EWP
CORT icon

Elevation Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

Elevation Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.3K Hold
176
– – 0.01% 676
2026
Q2 		$15.3K Buy
176
+30
+21% +$1.81K ﹤0.01% 669
2026
Q1 		$5.89K Buy
+146
New +$5.46K ﹤0.01% 664

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
RA
Riversedge Advisors Wilmington, Delaware $813M AUM 18.09% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Elevation Wealth Partners's CORT Position: Q3 2026 in Review

Elevation Wealth Partners held its Corcept Therapeutics (CORT) position steady in Q3 2026 at 176 shares worth $20.3K. The position accounts for 0.01% of the portfolio, ranked #676.

Elevation Wealth Partners first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Elevation Wealth Partners held 176 shares of Corcept Therapeutics worth $20.3K as of Q3 2026.
  • Elevation Wealth Partners left its Corcept Therapeutics share count unchanged in Q3 2026.
  • Corcept Therapeutics made up 0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #676 holding.
  • Elevation Wealth Partners first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.